Hemostasis valve market seen reaching $366.5M by 2033

Persistence Market Research projects the global hemostasis valve market will grow from $231.3 million in 2026 to $366.5 million by 2033, driven by more minimally invasive cardiovascular procedures and rising procedural volumes. North America is expected to stay the largest regional market, while hospitals and single-handed valves remain the biggest demand centers.

Why it matters: - Hemostasis valves are a critical accessory in catheter-based cardiovascular and vascular procedures. - Market growth signals rising use of minimally invasive interventions that can shorten recovery time and reduce surgical trauma. - Hospitals, device makers, and procedure centers are likely to see continued demand for blood-control and catheter-access tools.

What happened: - Persistence Market Research projected the global hemostasis valve market will reach $231.3 million in 2026 and $366.5 million by 2033. - The forecast implies a 6.8% compound annual growth rate from 2026 to 2033. - The forecast was released July 20, 2026. - The report said demand is being supported by expanding healthcare infrastructure and higher procedural volumes. - The report said North America will remain the leading regional market.

The details: - Single-handed hemostasis valves are expected to remain the leading product type because they are easier to operate and improve procedural efficiency. - Double-handed hemostasis valves remain part of the market, but the report said single-handed designs are seeing broader preference. - Hospitals are expected to dominate end-user demand because of higher patient inflow and advanced intervention facilities. - Specialty clinics and ambulatory surgical centers are increasing adoption as outpatient minimally invasive procedures expand. - The market spans product type, end user and application segments. - The report pointed to stronger valve durability, sealing performance and compatibility as key product improvements. - The report said demand is rising for user-friendly medical equipment that reduces procedural complexity.

Between the lines: - The growth outlook reflects a broader shift toward catheter-based care across cardiology, vascular medicine and radiology. - Manufacturers appear to be competing on ergonomics, sealing reliability and compatibility with newer interventional devices. - North America’s lead suggests mature healthcare systems and faster technology adoption still matter more than pure population growth. - Asia Pacific is expected to post strong growth as infrastructure expands and access to cardiovascular procedures improves. - Europe is described as a steadier market, supported by modernization of healthcare facilities.

What's next: - The report expects demand to stay elevated as cardiovascular disorder prevalence and complex vascular procedures increase. - Product innovation is likely to focus on improved sealing performance and broader device compatibility. - Emerging healthcare markets may offer the biggest expansion opportunities as hospital and diagnostic-center investment rises. - Strategic collaborations and new product launches are expected to support market growth through 2033.

The bottom line: - Hemostasis valves are on a steady growth path because minimally invasive procedures are becoming more common, and the market’s center of gravity remains with hospitals, single-handed products and North America.